Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jason O'Byrne - Executive VP & CFO Marianne De Backer - CEO & Director Mark D. Eisner - Executive VP & Chief Medical Officer Mika Kakefuda Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Avraham Leib Novick - Morgan Stanley, Research Division Huidong Wang - Barclays Bank PLC, Research Division Joseph Robert Stringer - Needham & Company, LLC, Research Division Mazahir Lukman Alimohamed - Leerink Partners LLC, Research Division Patrick Ralph Trucchio - H.C.
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $1.02 per share a year ago.
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vir Biotechnology: Hep B And Cancer Projects March On
Vir Biotechnology: Hep B And Cancer Projects March On
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Nick Gasic - Leerink Partners Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co. Joseph Stringer - Needham & Company Operator Hello.
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago.
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Hang Hu - Barclays Paul Choi - Goldman Sachs Phil Nadeau - TD Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham Patrick Trucchio - H.C. Wainwright & Co. Operator Hello.
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.86 per share a year ago.
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
Vir Biotechnology: A Rocket Off Phase 1 Data
Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation.
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
On Wednesday, Vir Biotechnology, Inc. VIR stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC).
